{"id":49419,"date":"2023-06-30T11:42:00","date_gmt":"2023-06-30T11:42:00","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=49419"},"modified":"2023-07-11T05:47:30","modified_gmt":"2023-07-11T05:47:30","slug":"evaluation-of-acetylcholinesterase-and-acetylcholine-levels-in-children-with-idiopathic-epilepsy","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol16no2\/evaluation-of-acetylcholinesterase-and-acetylcholine-levels-in-children-with-idiopathic-epilepsy\/","title":{"rendered":"Evaluation of Acetylcholinesterase and Acetylcholine Levels in Children with Idiopathic Epilepsy."},"content":{"rendered":"\n

Introduction<\/strong><\/p>\n\n\n\n

Epilepsy affected the development of learning and cognitive functionsvia a number of numerous factors: etiology 1<\/sup> age of onset, seizure type2,3<\/sup> duration and severity, interictal epileptic form discharges,4<\/sup>drug treatment. Epilepsy is a devastating neurological and systemic disorder characterized by recurrent seizures5<\/sup>. Despite the rapid progression in clinical and pre-clinical epilepsy research, the pathogenesis of epilepsy still remains elusive. <\/p>\n\n\n\n

Acetylcholinesterase (AChE) has a significant role in the pathogenesis of neurodegenerative diseases by inducing aggregation of pathological proteins, oxidative stress, apoptosis, and inflammatory response. Diminished AChE concentrations cause irregularly augmented concentrations of ACH in cholinergic synapses, producing unnecessary nicotinic receptors and muscarinic stimulation 6<\/sup>. Researches associated to ACh on the vagus nerve for epilepsy were imperative to elucidate inflammations in epilepsy. The present work will explore the predictive role of AChEand ACH for idiopathic epilepsy and how it is related to clinical features of the patients.<\/p>\n\n\n\n

Subjects and Methods  <\/strong><\/p>\n\n\n\n

Subjects<\/strong><\/p>\n\n\n\n

The study comprised three\ngroups of children, 30 children with drug resistant epilepsy,30 with seizures\nfree and 30 age and sex matched healthy children.<\/p>\n\n\n\n

Methods<\/strong><\/p>\n\n\n\n

Assessment <\/strong>of Acetyl cholinesterase\nActivity(AChE)<\/strong><\/p>\n\n\n\n

Acetyl cholinesterase Activity was assessed\nby a double-antibody sandwichenzyme-linked immunosorbent assay ELISA kit from\nShanghai Biovision Co., Ltd, Jufengyuan Road, Baoshan District, Shanghai.<\/p>\n\n\n\n

Assessment of acetylcholine Activity\n<\/strong><\/p>\n\n\n\n

Thetechniquewasdesignated for\nreversed-phase HPLC separation of acetylcholine of their homologues in serum, united\nwith post columnfluorometric quantification and enzymatic derivatization. The\nseparation happens on a polymeric resin derivatized with hydrophobic moiety and\nthe mobile phase comprises Na2<\/sub>HPO4<\/sub>. 3-(p<\/em>-hydroxyphenyl)sodium\ndodecylsulphate; propionate and post column enzyme reactor comprises\nimmobilized choline oxidase, peroxidase and acetyl cholinesterase. Method is well\nsuited for non-attended automatic operation and free of encountered interferences\nwith electrochemical detection.<\/p>\n\n\n\n

Ethical Approval<\/strong><\/p>\n\n\n\n

This research was approved by the\nEthical Committee of Al-Azhar\nUniversity (No: 00782) and followed the World Medical Association\u2019s\nDeclaration of Helsinki. Furthermore, each participant in the study signed a\nwritten consent after a full description of the study.<\/p>\n\n\n\n

Statistical analysis<\/strong><\/p>\n\n\n\n

Statistical analysis was performed using SPSS\nversion 21 for windows. Data were expressed as mean \u00b1 standard\ndeviation and compared to t-test to compare between two groups. ANOVA and post\nhoc tests for comparing between more than 2 groups. Data were expressed as percentages\nand frequencies, and were analyzed with the two-tailed chi square test. <\/strong><\/p>\n\n\n\n

Results<\/strong><\/p>\n\n\n\n

Chalfont severity score was significantly increases in drug resistance epilepsy cases than seizure free and controls (Table 1). Significant lower levels of AChE was found in drug resistant epilepsy compared to seizure free epilepsy and healthy controls[MF6]  (p < 0.05). Lower ACH levels was found in seizure free epilepsy compared to drug resistant epilepsy and healthy controls (p < 0.05) (Table 2). Stepwise linear regression analysis showed that ACHE, ACH, severity score are significant independent factors associated with idiopathic epilepsy (Table 3). Moreover, Receiver Operating Characteristic (ROC analysis showed that severity score at cutoff of Chlfont score>60 had the highest sensitivity 86.7% and specificity 80% followed by serum ACHE at cutoff < 3.212 (ng\/ml) with sensitivity 70% and specificity 100% and then serum ACH at cutoff > 18.410 (ng\/ml) with sensitivity 70% and specificity 83.3% as predictors for idiopathic epilepsy.<\/p>\n\n\n\n

Table 1: Electroencephalographic findings and clinical data in children with drug resistant epilepsy & seizure free children<\/strong>.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
 <\/td>\n\n

drug resistant epilepsy (n=30)
Mean \u00b1 SD<\/strong><\/p>\n<\/td>\n

\n

seizure free <\/strong><\/p>\n

(n=30)
Mean \u00b1 SD<\/strong><\/p>\n<\/td>\n

\n

Independent T test\/ chi square test<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

t\/x2<\/sup><\/strong><\/p>\n<\/td>\n

\n

p-value<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

 Age<\/strong> (years)<\/p>\n<\/td>\n

\n

9.013\u00b11.426<\/p>\n<\/td>\n

\n

9.277\u00b10.871<\/p>\n<\/td>\n

\n

-0.863<\/p>\n<\/td>\n

\n

0.392<\/p>\n<\/td>\n<\/tr>\n

\n

Gender (N, %)<\/strong><\/p>\n

Male<\/p>\n

Female<\/p>\n<\/td>\n

\n

20 (66.7%)<\/p>\n

10 (33.3%)<\/p>\n<\/td>\n

\n

22 (73.3%)<\/p>\n

8 (26.7%)<\/p>\n<\/td>\n

\n

0.317<\/p>\n<\/td>\n

\n

0.573<\/p>\n<\/td>\n<\/tr>\n

\n

Age of onset of seizures <\/strong>(years)<\/p>\n<\/td>\n

\n

3.233\u00b11.670<\/p>\n<\/td>\n

\n

3.783\u00b12.104<\/p>\n<\/td>\n

\n

1.122<\/p>\n<\/td>\n

\n

0.267<\/p>\n<\/td>\n<\/tr>\n

\n

Duration of disease<\/strong> (years)<\/p>\n<\/td>\n

\n

5.687\u00b11.523<\/p>\n<\/td>\n

\n

6.667\u00b13.384<\/p>\n<\/td>\n

\n

1.446<\/p>\n<\/td>\n

\n

0.153<\/p>\n<\/td>\n<\/tr>\n

\n

Chalfont severity score<\/strong><\/p>\n<\/td>\n

\n

91.733\u00b120.120<\/p>\n<\/td>\n

\n

48.867\u00b116.950<\/p>\n<\/td>\n

\n

8.925<\/p>\n<\/td>\n

\n

<0.0001<\/p>\n<\/td>\n<\/tr>\n

\n

Type of epilepsy (N, %)<\/strong><\/p>\n

Focal<\/p>\n

Generalized<\/p>\n

Focal with secondary generalization<\/p>\n<\/td>\n

\n

 <\/p>\n

22 (73.3%)<\/p>\n

6 (20%)<\/p>\n

2 (6.7%)<\/p>\n<\/td>\n

\n

 <\/p>\n

13 (43.3%)<\/p>\n

13 (43.3%)<\/p>\n

4 (12.3%)<\/p>\n<\/td>\n

\n

5.560<\/p>\n<\/td>\n

\n

0.062<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*p < 0.05<\/p>\n\n\n

Table 2: AChE and ACH serum levels in epilepticchildren and healthy children<\/strong>.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

 <\/p>\n<\/td>\n

\n

Seizure free Children <\/strong><\/p>\n

(n=30)
Mean \u00b1 SD<\/strong><\/p>\n<\/td>\n

\n

Children with drug resistant epilepsy<\/strong><\/p>\n

(n=30)
Mean \u00b1 SD<\/strong><\/p>\n<\/td>\n

\n

Healthy children<\/strong><\/p>\n

(n=30)<\/strong><\/p>\n

Mean \u00b1 SD<\/strong><\/p>\n<\/td>\n

\n

ANOVA test<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

F<\/strong><\/p>\n<\/td>\n

\n

p-value<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

(ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

3.646\u00b16.601<\/p>\n<\/td>\n

\n

1.969\u00b11.129<\/p>\n<\/td>\n

\n

4.550\u00b12.870<\/p>\n<\/td>\n

\n

71.656<\/p>\n<\/td>\n

\n

<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

ACH (ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

29.705\u00b118.042<\/p>\n<\/td>\n

\n

12.818\u00b15.253<\/p>\n<\/td>\n

\n

10.065\u00b17.811<\/p>\n<\/td>\n

\n

23.755<\/p>\n<\/td>\n

\n

<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

Post hoc analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

 <\/p>\n<\/td>\n

\n

Seizure free vs drug resistantepilepsy<\/strong><\/p>\n<\/td>\n

\n

Seizure freevshealthy children<\/strong><\/p>\n<\/td>\n

\n

drug resistant epilepsy vs healthy children<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

AChE(ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

0.202<\/p>\n<\/td>\n

\n

<0.01**<\/p>\n<\/td>\n<\/tr>\n

\n

ACH (ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

0.375<\/p>\n<\/td>\n

\n

<0.01**<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

**p < 0.01<\/p>\n\n\n\n

Table 3: Liner stepwise regression analysis for prediction of drug resistantepilepsy in idiopathic epileptic children<\/strong>.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Coefficients<\/strong><\/p>\n<\/td>\n

\n

Unstandardized Coefficients<\/strong><\/p>\n<\/td>\n

\n

Standardized Coefficients<\/strong><\/p>\n<\/td>\n

\n

t<\/strong><\/p>\n<\/td>\n

\n

P-value<\/strong><\/p>\n<\/td>\n

\n

95.0% Confidence Interval for B<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Model<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n

\n

B<\/p>\n<\/td>\n

\n

Std. Error<\/p>\n<\/td>\n

\n

Beta<\/p>\n<\/td>\n

 <\/td>\n <\/td>\n\n

Lower Bound<\/p>\n<\/td>\n

\n

Upper Bound<\/p>\n<\/td>\n<\/tr>\n

\n

1<\/p>\n

 <\/p>\n<\/td>\n

\n

(Constant)<\/p>\n<\/td>\n

\n

3.449<\/p>\n<\/td>\n

\n

0.115<\/p>\n<\/td>\n

 <\/td>\n\n

30.108<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

3.22<\/p>\n<\/td>\n

\n

3.678<\/p>\n<\/td>\n<\/tr>\n

\n

score<\/p>\n<\/td>\n

\n

-0.013<\/p>\n<\/td>\n

\n

0.002<\/p>\n<\/td>\n

\n

-0.761<\/p>\n<\/td>\n

\n

-8.925<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

-0.017<\/p>\n<\/td>\n

\n

-0.01<\/p>\n<\/td>\n<\/tr>\n

\n

2<\/p>\n

 <\/p>\n

 <\/p>\n<\/td>\n

\n

(Constant)<\/p>\n<\/td>\n

\n

3.421<\/p>\n<\/td>\n

\n

0.102<\/p>\n<\/td>\n

 <\/td>\n\n

33.625<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

3.217<\/p>\n<\/td>\n

\n

3.625<\/p>\n<\/td>\n<\/tr>\n

\n

score<\/p>\n<\/td>\n

\n

-0.008<\/p>\n<\/td>\n

\n

0.002<\/p>\n<\/td>\n

\n

-0.467<\/p>\n<\/td>\n

\n

-4.492<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

-0.012<\/p>\n<\/td>\n

\n

-0.005<\/p>\n<\/td>\n<\/tr>\n

\n

ACHE<\/p>\n<\/td>\n

\n

-0.03<\/p>\n<\/td>\n

\n

0.007<\/p>\n<\/td>\n

\n

-0.427<\/p>\n<\/td>\n

\n

-4.105<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

-0.045<\/p>\n<\/td>\n

\n

-0.015<\/p>\n<\/td>\n<\/tr>\n

\n

3<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n<\/td>\n

\n

(Constant)<\/p>\n<\/td>\n

\n

3.393<\/p>\n<\/td>\n

\n

0.097<\/p>\n<\/td>\n

 <\/td>\n\n

35.093<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

3.199<\/p>\n<\/td>\n

\n

3.586<\/p>\n<\/td>\n<\/tr>\n

\n

score<\/p>\n<\/td>\n

\n

-0.007<\/p>\n<\/td>\n

\n

0.002<\/p>\n<\/td>\n

\n

-0.412<\/p>\n<\/td>\n

\n

-4.112<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

-0.011<\/p>\n<\/td>\n

\n

-0.004<\/p>\n<\/td>\n<\/tr>\n

\n

ACHE<\/p>\n<\/td>\n

\n

-0.059<\/p>\n<\/td>\n

\n

0.013<\/p>\n<\/td>\n

\n

-0.846<\/p>\n<\/td>\n

\n

-4.723<\/p>\n<\/td>\n

\n

<0.0001*<\/p>\n<\/td>\n

\n

-0.084<\/p>\n<\/td>\n

\n

-0.034<\/p>\n<\/td>\n<\/tr>\n

\n

ACH<\/p>\n<\/td>\n

\n

0.014<\/p>\n<\/td>\n

\n

0.005<\/p>\n<\/td>\n

\n

0.433<\/p>\n<\/td>\n

\n

2.799<\/p>\n<\/td>\n

\n

0.007*<\/p>\n<\/td>\n

\n

0.004<\/p>\n<\/td>\n

\n

0.024<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

*p < 0.05 <\/p>\n\n\n\n

Table 4: Predictive values, specificity and Sensitivity for prediction of drug resistant epilepsy in babies with idiopathic epilepsy<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
\n

variables<\/strong><\/p>\n<\/td>\n

\n

AUC<\/strong><\/p>\n<\/td>\n

\n

Cutoff point<\/strong><\/p>\n<\/td>\n

\n

Sensitivity<\/strong><\/p>\n<\/td>\n

\n

Specificity<\/strong><\/p>\n<\/td>\n

\n

95% Confidence Interval<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Lower Bound<\/strong><\/p>\n<\/td>\n

\n

Upper Bound<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Chalfont score<\/strong><\/p>\n<\/td>\n

\n

0.943<\/p>\n<\/td>\n

\n

>60<\/p>\n<\/td>\n

\n

86.7%<\/p>\n<\/td>\n

\n

80%<\/p>\n<\/td>\n

\n

0.892<\/p>\n<\/td>\n

\n

0.994<\/p>\n<\/td>\n<\/tr>\n

\n

Serum ACHE (ng\/ml) <\/strong><\/p>\n<\/td>\n

\n

0.995<\/p>\n<\/td>\n

\n

<3.212<\/p>\n<\/td>\n

\n

70%<\/p>\n<\/td>\n

\n

100%<\/p>\n<\/td>\n

\n

0.984<\/p>\n<\/td>\n

\n

1.000<\/p>\n<\/td>\n<\/tr>\n

\n

Serum ACH (ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

0.786<\/p>\n<\/td>\n

\n

>18.410<\/p>\n<\/td>\n

\n

70%<\/p>\n<\/td>\n

\n

83.3%<\/p>\n<\/td>\n

\n

0.659<\/p>\n<\/td>\n

\n

0.913<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

AUC: area under curve; <\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Figure 1: <\/strong>ROC (Receiver Operating <\/strong>Characteristic) curve for predictors of drug resistant epilepsy in children with idiopathic epilepsy<\/strong><\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Discussion<\/strong><\/p>\n\n\n\n

Proinflammatory\nmediators couldamendexcitability of the neurons and affect neurotransmission causingreductionin\nthe seizures threshold and increase neuronal damage7<\/sup>,<\/sup>8<\/sup>.Cytokines have been involved as inhibitors\nand mediators of various forms of neurodegeneration9<\/sup>,<\/sup>10<\/sup>,<\/sup>11<\/sup>. Pro-inflammatory cytokine in the\ninnate immune response modulates fundamental processes in the brain 10,12<\/sup>.<\/p>\n\n\n\n

The influence of neuromodulators implicated\nin the impulses transmission on the pathogenesis is of immensesignificanceas\nepileptic seizures happen with the disturbance of the inhibitory-excitatory\nbalance in the brain. Consequently, mutations\/disorders of the elements at the ion\nchannel level and receptor mightcausestimulus transmission abnormality and\nepileptic discharges. Diminished levels of AChEcause abnormally elevatedlevels\nof ACH in cholinergicsynapses, leading toexaggerated stimulation of nicotinic\nand muscarinic receptors13\u201315<\/sup>.Neurotransmitters mainly ACH has been involved in the epilepsy\u2019s pathogenesis\nas proved via their amendment in pre-clinical model of epileptic seizure16<\/sup>.Amongst the variousparticipating influences underlying the seizures\ngeneration\u2019s mechanism, the role of neurotransmitters has been involved in the\nsame. Neurotransmitters are endogenous constituents that transfer signals\nacross the synapse and controlexcitatory\/ inhibitory neuronal functions through\nfastening to their particular receptors. Usually it is stored in axon\nterminals,synaptic vesicles and secreted into the synapse followinganappropriate\nsignal. Liberatedneurotransmitterscarry out the connecting functions over the\nsynaptic cleft and fastening to particular receptors. Gut microbiotacould\nmodulate brain behavior and function and is highlydocumented as an imperative\nfactor in mediating the risk of epilepsy and the impacts of seizure\ninterventions17,18<\/sup><\/p>\n\n\n\n

Conclusion<\/strong><\/p>\n\n\n\n

In conclusion, investigating the\nrelations of ACH and AChE that are the major actors in epilepsy has become an imperative\naim to elucidate the underlying pathology in neurological disorders.<\/p>\n\n\n\n

Conflicts of Interest <\/strong><\/p>\n\n\n\n

There are no conflict of interest.<\/p>\n\n\n\n

References<\/strong><\/p>\n\n\n\n

  1. Beghi E, Cornaggia CM, Elia M. Proposal for a multicenter study on epilepsy and learning disorders in children. Epilepsia<\/em>. 2001;42(1):10-12.
    CrossRef<\/a><\/li>
  2. Bourgeois BFD, Prensky AL, Palkes HS, Talent BK, Busch SG. Intelligence in epilepsy: a prospective study in children. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc<\/em>. 1983;14(4):438-444.
    CrossRef <\/a><\/li>
  3. Holmes GL. Pathogenesis of learning disabilities in epilepsy. Epilepsia<\/em>. 2001;42:13-15.
     CrossRef <\/a><\/li>
  4. Binnie CD. Cognitive performance, subtle seizures, and the EEG. Epilepsia<\/em>. 2001;42:16-18.
     CrossRef <\/a><\/li>
  5. Devinsky O, Vezzani A, O\u2019Brien TJ, et al. Epilepsy Nat Rev Dis Primers 4: 18024. 2018.
    CrossRef <\/a><\/li>
  6. Aboul Ezz HS, Khadrawy YA, Noor NA. The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochem Res<\/em>. 2011;36(11):2195-2204.
    CrossRef <\/a><\/li>
  7. Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy. Acta Neuropathol<\/em>. 2016;131(2):211-234.
     CrossRef <\/a><\/li>
  8. Suleymanova EM. Behavioral comorbidities of epilepsy and neuroinflammation: Evidence from experimental and clinical studies. Epilepsy Behav<\/em>. 2021;117:107869. doi:https:\/\/doi.org\/10.1016\/ j.yebeh.2021.107869
    CrossRef <\/a><\/li>
  9. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci<\/em>. 2001;2(10):734-744.
     CrossRef <\/a><\/li>
  10. Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J neuroimmune Pharmacol<\/em>. 2012;7(1):42-59.
     CrossRef <\/a><\/li>
  11. Rothwell NJ. The role of cytokines in neurodegeneration. In: Cytokines in the Nervous System<\/em>. Springer; 1996:145-162.
     CrossRef <\/a><\/li>
  12. Zalpoor H, Akbari A, Samei A, et al. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies. Cell Mol Biol Lett<\/em>. 2022;27(1):1-21.
    CrossRef <\/a><\/li>
  13. Chen ET, Thornton JT, Mulchi Jr C. Early forming a hummingbird-like hovering neural network circuitry pattern with reentrant spatiotemporal energy-sensory orientation privileged to avoid \u201cEpilepsy\u201d based on a biomimetic acetylcholinesterase memcapacitor prosthesis. Sensors & Transducers<\/em>. 2015;191(8):84-99.<\/li>
  14. Mishra A, Goel RK. Psychoneurochemical investigations to reveal neurobiology of memory deficit in epilepsy. Neurochem Res<\/em>. 2013;38(12):2503-2515.
     CrossRef <\/a><\/li>
  15. Arend J, Kegler A, Caprara ALF, et al. Depressive, inflammatory, and metabolic factors associated with cognitive impairment in patients with epilepsy. Epilepsy Behav<\/em>. 2018;86:49-57.
     CrossRef <\/a><\/li>
  16. Akyuz E, Polat AK, Eroglu E, Kullu I, Angelopoulou E, Paudel YN. Revisiting the role of neurotransmitters in epilepsy: An updated review. Life Sci<\/em>. 2021;265:118826.
    CrossRef <\/a><\/li>
  17. Li X, Wang Q, Wu D, et al. The effect of a novel anticonvulsant chemical Q808 on gut microbiota and hippocampus neurotransmitters in pentylenetetrazole-induced seizures in rats. BMC Neurosci<\/em>. 2022;23(1):7. doi:10.1186\/s12868-022-00690-3
    CrossRef <\/a><\/li>
  18. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res<\/em>. 2018;1693:128-133.
     CrossRef <\/a><\/li><\/ol>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    Introduction Epilepsy affected the development of learning and cognitive functionsvia […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[107],"tags":[],"class_list":["post-49419","post","type-post","status-publish","format-standard","hentry","category-vol16no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=49419"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49419\/revisions"}],"predecessor-version":[{"id":50148,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49419\/revisions\/50148"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=49419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=49419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=49419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}